Natalizumab Exerts Direct Signaling Capacity and Supports a Pro-Inflammatory Phenotype in Some Patients with Multiple Sclerosis

Natalizumab is a recombinant monoclonal antibody raised against integrin alpha-4 (CD49d). It is approved for the treatment of patients with multiple sclerosis (MS), a chronic inflammatory autoimmune disease of the CNS. While having shown high therapeutic efficacy, treatment by natalizumab has been l...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Benkert, Thomas F., Dietz, Lena, Hartmann, Elena M., Leich, Ellen, Rosenwald, Andreas, Serfling, Edgar, Buttmann, Mathias, Berberich-Siebelt, Friederike
Format: Artigo
Langue:Inglês
Publié: Public Library of Science 2012
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3527399/
https://ncbi.nlm.nih.gov/pubmed/23284936
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0052208
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires